BLA 761042 · Sandoz
Erelzi
Etanercept-Szzs · Injection
Last checked: Nov 20, 2026Latest source record: Nov 10, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Aug 30, 2016
Approved uses
4
Original approval plus efficacy supplements
Registered trials
373
108 Phase 3, 17 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 10, 2022 Supplement 18 · Efficacy LabelMedication GuideLetter
- Jun 11, 2020 Supplement 12 · Efficacy LetterLabel
- Oct 18, 2019 Supplement 10 · Efficacy LabelLetter
- Aug 30, 2016 Original approval LetterLabelReview
2 products under this application
- ERELZI · ETANERCEPT-SZZS 50MG/ML · INJECTABLE, INJECTION · Prescription
- ERELZI · ETANERCEPT-SZZS 25MG/0.5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Etanercept" as an intervention, any sponsor and status, largest first.
- Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02092467 · 4,372 participants · Start Mar 14, 2014 · Primary completion Jul 22, 2020
Drug: tofacitinib; tofacitinib and 2 more · For: Arthritis, Rheumatoid
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 345 sites in all
- A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk FactorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01331837 · 3,080 participants · Start Aug 2, 2011 · Primary completion Mar 25, 2016
Drug: Etanercept; Tocilizumab · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 428 sites in all
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03915964 · 2,659 participants · Start Apr 25, 2019 · Primary completion May 28, 2025
Drug: Baricitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Flagstaff, Arizona; Gilbert, Arizona; Glendale, Arizona · 261 sites in all
- A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01646177 · 1,346 participants · Start Jul 28, 2012 · Primary completion May 22, 2014
Drug: Placebo; 50 mg etanercept and 1 more · For: Psoriasis
Sites: Anaheim, California; Bakersfield, California; Bell Gardens, California · 101 sites in all
- Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type PsoriasisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01358578 · 1,306 participants · Start Jun 2011 · Primary completion Jul 2013
Drug: Placebo; secukinumab (AIN457) and 1 more · For: Chronic Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 152 sites in all
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00124982 · 1,286 participants · Start Apr 2005 · Primary completion Aug 2009
Drug: Abatacept; Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Paradise Valley, Arizona · 148 sites in all
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01597245 · 1,224 participants · Start May 18, 2012 · Primary completion Mar 25, 2014
Drug: 80 mg ixekizumab Dosing Regimen; 50 mg etanercept and 1 more · For: Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 118 sites in all
- A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01241591 · 1,101 participants · Start Nov 2010 · Primary completion Jan 2013
Drug: CP 690,550 5 mg; CP 690,550 10 mg and 1 more · For: Psoriasis
Sites: Buenos Aires, Argentina; Feldkirch, Austria; Innsbruck, Austria · 122 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
- Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
Wang CW, Yang LY, Chen CB, et al. · J Clin Invest 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Huang IH, Wu PC, Chiu HY, et al. · Am J Clin Dermatol 2024 · Systematic Review, Comparative Study
- Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
Jacobsen A, Olabi B, Langley A, et al. · Cochrane Database Syst Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
Giles JT, Sattar N, Gabriel S, et al. · Arthritis Rheumatol 2020 · Comparative Study, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.